STING-LNP

STING-LNP is a preclinical intravenously administered lipid-nanoparticle formulation developed at Hokkaido University to deliver the cyclic dinucleotide STING agonist c-di-GMP into immune cells. The reported formulation is primarily composed of the ionizable lipid YSK12-C4, cholesterol, and DMG-PEG2k, encapsulating c-di-GMP. Following liver uptake by macrophages, it activates STING-dependent type I interferon signaling, systemically stimulates natural killer cells, and has shown antitumor activity in mouse models of melanoma lung metastasis and renal cell carcinoma lung metastasis. In a B16-F10 melanoma lung-metastasis model resistant to PD-1 blockade, STING-LNP increased NK-cell activation and tumor PD-L1 expression, producing synergistic antitumor activity when combined with anti-PD-1 treatment. ([jitc.bmj.com](https://jitc.bmj.com/content/9/7/e002852))

Other names

STING agonist-loaded lipid nanoparticleSTING agonist-loaded lipid nanoparticlesSTING-LNPs